国药现代：全资子公司国药容生获得注射用尼可地尔药品注册证书

Group 1 - The core point of the article is that China National Pharmaceutical Group Modern (国药现代) announced that its wholly-owned subsidiary, China National Pharmaceutical Container (国药容生), received approval from the National Medical Products Administration for the injection of Nicorandil, which is primarily used for treating unstable angina pectoris [1] - Nicorandil was originally developed by Japan's Chugai Pharmaceutical Co., Ltd. and was approved for marketing in Japan in 1993 [1]